Super-operation is finalized / Dangerous drugs enter Albania, police handcuff the person who possessed it (DETAILS)
Dy persona janë arrestuar në kuadër të operacionit të koduar “MDMA” në Vlorë
Source: sot.com.al
Page 23 - Himara News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Himara. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Himara Today - Breaking & Trending Today
IMARA (NASDAQ:IMRA) Downgraded by Zacks Investment Research
IMARA (NASDAQ:IMRA – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. According to Zacks, “Imara Inc. is a biopharmaceutical company. It engages in developing and commercializing novel therapeutics to treat patients suffering from rare […]
Source: etfdailynews.com
IMARA Inc. (NASDAQ:IMRA) Short Interest Down 26.9% in May
IMARA Inc. (NASDAQ:IMRA – Get Rating) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 194,400 shares, a decline of 26.9% from the April 30th total of 265,800 shares. Based on an average daily volume of 383,300 shares, the days-to-cover ratio is presently […]
Source: etfdailynews.com
Zacks Investment Research Upgrades IMARA (NASDAQ:IMRA) to "Buy"
IMARA (NASDAQ:IMRA – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday, Zacks.com reports. The brokerage presently has a $1.50 price objective on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 30.43% from the company’s current price. […]
Source: etfdailynews.com
IMARA (NASDAQ:IMRA) Lowered to Hold at Zacks Investment Research
IMARA (NASDAQ:IMRA – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports. According to Zacks, “Imara Inc. is a biopharmaceutical company. It engages in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders […]
Source: etfdailynews.com